721 results about "Hepatocyte" patented technology

The invention provides a multi-modal large language model for generating a hepatocellular carcinoma key pathological diagnosis report, a framework main body is a visual coding module, and a multi-modal feature alignment module, a multi-head low-rank attention mechanism, an enhanced medical MoE mechanism and a structured output decoding layer are also introduced. The visual coding module is constructed on the basis of a Swin Transform architecture, visual pre-training is completed on hepatocellular carcinoma MRI data, and after a task specific classification head is stripped, a trunk feature extraction network is reserved to serve as an image modal representation encoder. The multi-modal feature alignment module guides the model to learn a cross-modal semantic mapping relation between a hepatocellular carcinoma MRI image and a key pathological diagnosis report language, image modal input is a visual feature sequence, and text modal output is a structured description text; and the structured output decoding layer generates six types of liver cancer focus attributes. According to the method, the pre-operative multi-parameter and multi-stage enhanced MRI image is utilized, and the open-source large model is finely adjusted to generate a matched liver cancer postoperative pathology report.

The invention discloses a hepatocellular carcinoma postoperative early recurrence prediction method based on multi-modal fusion. The method comprises the following steps: firstly, integrating clinical data of a training set, a preoperative enhanced CT image and a postoperative full-view digital pathological image, and carrying out standardized correction; then, traditional image omics features and deep learning features are extracted from the CT image, cell nucleus morphological features and tumor microenvironment spatial configuration features are extracted from the pathological image, and key feature signatures are screened out through a maximum correlation minimum redundancy algorithm (mRMR) and LASSO regression in combination with clinical features. And then carrying out progressive model construction by adopting an XGBoost algorithm, sequentially establishing a clinical single-mode model, an image single-mode model, a pathological single-mode model and a multi-mode fusion model, and explaining and visualizing the models by utilizing an SHAP value and a Grad-CAM technology. Finally, the performance of the model is evaluated in a multi-dimensional mode through internal cross validation, foresight and external independent validation, risk layering is carried out based on the prediction probability, and individualized postoperative management is guided.

Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.

Disclosed in the present invention are a biomimetic vascularized iPSC-hep spheroid for liver regeneration, and a preparation method therefor. The biomimetic vascularized iPSC-hep spheroid is a microcapsule with a porous hyaluronic acid methacryloyl as a shell and a human-induced pluripotent stem-cell-derived hepatocyte spheroid as an inner phase, and human umbilical vein endothelial cells adhere to the surface of the shell. The biomimetic vascularized iPSC-hep spheroid of the present invention promotes effective communication between hiPSC-heps and HUVECs, and provides barrier protection for an encapsulated hiPSC-hep spheroid so as to avoid attack by the immune system. Compared with dispersed cells, the cell-to-cell interaction in the cell spheroid improves cell-to-cell communication, helps to simulate the physiological heterogeneous structure and cell microenvironment of the liver, and can more effectively repair an acutely failing liver.

The invention belongs to the technical field of cell biology, and particularly discloses a culture medium and a culture method of fish primary liver cells. The culture medium of the fish primary liver cells comprises the following components: 90% of an M199 culture medium, 10% of fetal calf serum, 100 U / mL of penicillin, 0.1 mg / mL of streptomycin, 5 ng / mL of EGF, 10 [mu] U / ml of insulin and 10 mM of dexamethasone. Based on the culture medium, an efficient and stable fish liver cell culture method is developed by combining a standardized anesthesia and disinfection process, a precise dissection and liver sampling method, an optimized tissue digestion and cell separation scheme, an efficient cell purification and adherent culture system, a stable passage technology and the like; a standardized hepatocyte line establishment operation process is defined, and the problems that species binding exists in an existing fish liver cell culture method, and a standardized culture process suitable for multiple fish fingerlings is difficult to form are solved.

The invention discloses a bioreactor multi-parameter adaptive control system and method based on machine learning, and belongs to the technical field of bioreactor intelligent control, and the bioreactor multi-parameter adaptive control system comprises a bioreactor hepatocyte culture unit, a data acquisition and control unit and a machine learning intelligent decision-making unit. And the data acquisition and control lower computer controls operation variables such as gas supply, sampling and perfusion in the culture unit execution mechanism, collects culture process data returned by the parameter detection module, constructs a data-driven cell state prediction model by utilizing machine learning, and optimizes model parameters and operation variables based on a prediction result to realize closed-loop control. The method can overcome the defect that there is no precise mechanism model for hepatic cell culture, and multi-parameter collaborative optimization can be realized only depending on process data, so that the state of the hepatic cells is sensed in real time, full-cycle optimization of cell viability and functions is realized, and the activity and density of hepatic cell culture are effectively improved.

The invention discloses a Hu sheep primary hepatocyte separation effect intelligent evaluation system based on image recognition, and belongs to the technical field of biomedical engineering and intelligent detection. The physical mapping relation between the non-uniform illumination light field and the three-dimensional curved surface form and the tension state of the optical soft spherical shell is established; and the data field generation module is used for projecting serialized structured light based on the physical mapping relation, collecting a bright field image sequence generated by the structured light, synchronously collecting a fluorescence image, carrying out physical field association on modulation information carried by the bright field image sequence and topological information of the fluorescence image, and generating a high-dimensional native response data field. According to the method, the contact ridge line of the high-density adhesion Hu sheep primary hepatocytes can be accurately identified by constructing the optical soft spherical shell model and coupling mapping of the light field and the physical state of the cells, the problems of under-segmentation and over-segmentation are effectively avoided, and the extracted morphological parameters such as the area and the perimeter of the cells better fit the reality.

The present invention relates to the new use of an exosome secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and in particular relates to the use of the exosome in the preparation of a drug for treating liver diseases. The exosome is secreted by hepatocyte lineage cells differentiated via the directed induction of embryonic stem cells, and the hepatocyte lineage cells are hepatic progenitor cells and / or mature hepatocyte-like cells.

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention discloses liver peptide capable of protecting liver and improving asthenopia as well as a preparation method and application of the liver peptide, and belongs to the technical field of biology. The liver peptide contains at least one of DAIP, SPF, DIAP, SLP, AVGP or NLP, and the prepared liver peptide has multiple physiological effects: the liver peptide can effectively activate ADH enzyme activity, reduce ALT and AST levels and protect liver cells; the lipid metabolism is improved by regulating and controlling the expression of the SREBP-1c, the FAS and the PPAR-alpha genes; meanwhile, the antioxidant capacity is remarkable, the ROS level can be reduced, and the SOD content and the CAT content can be increased; the expression of RPE65 and LRAT genes can be up-regulated, and the visual function is maintained. The method disclosed by the invention is simple in process and convenient to operate, the obtained liver peptide can be widely applied to the field of functional products for protecting the liver, improving visual fatigue and the like, and an innovative solution is provided for high-value utilization of liver resources.

Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.

The invention discloses a hepatocellular carcinoma prognosis and immune response prediction method based on multi-omics machine learning, and relates to the technical field of biomedicine and artificial intelligence crossing, and the method comprises the following steps: S1, constructing a multi-omics data set for model training and verification; s2, performing feature integration and clustering analysis on the multi-omics data to obtain corresponding hepatocellular carcinoma molecular subtype distribution; s3, constructing a hepatocellular carcinoma prognosis model based on Cox regression combined with a random survival forest, identifying 11 core immune genes and corresponding weight coefficients by training the model, and constructing an immunotherapy response index IMLIRI score; and S4, carrying out clinical application on the IMLIRI score. According to the method, through multi-omics data integration and multi-queue external verification, the influence of data deviation and queue heterogeneity on the model performance is reduced, so that the method shows stable prediction performance in hepatocellular carcinoma queues with different sources and different pathogenesis backgrounds, and the reliability and generalizability of the model in clinical application are improved.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The application discloses application of a compound ZML1 in preparation of a medicine for treating acute drug-induced liver injury. Through in-vivo and in-vitro experiments, it is found that ZML1 can reverse acute liver injury only by acting for several hours, for example, restoring normal morphology of hepatocytes, reducing lipid deposition, rapidly improving damage performance of various transaminases and the like. The treatment effect of the compound ZML1 of the application on various liver injury indexes is superior to that of existing liver-protecting medicines, especially in improving lipid deposition of hepatocytes, and the compound ZML1 shows more excellent curative effect. Therefore, ZML1 has excellent drug property in treating acute drug-induced liver injury and protecting liver, and thus has a wide application prospect.

This invention discloses a hepatocyte model with silencing or overexpression of LCMT1 and its construction method, comprising: passage and seeding cells in logarithmic growth phase into well plates; diluting plasmid siRNA1 or siRNA2 or an overexpression plasmid to an appropriate concentration, and then mixing it with transfection reagent dilution to obtain a transfection mixture; washing the cells in each well of the plate and adding another culture medium, then gently dripping the transfection mixture into the well plate, shaking well, and culturing in a cell culture incubator for a period of time; replacing the culture medium with complete culture medium without antibiotics to obtain the constructed hepatocyte model with silencing or overexpression of LCMT1. This invention, by constructing a hepatocyte model with silencing or overexpression of LCMT1 in the liver, allows for validation experiments to be conducted to study the development mechanism of liver fibrosis. It is suitable for widespread application in various laboratories and provides an experimental model basis for research on liver fibrosis and drug trials.

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

This invention discloses a virulent strain of type I canine adenovirus and its application in constructing animal infection models, belonging to the field of biotechnology. The virulent strain of type I canine adenovirus is named canine adenovirus type 1 strain 0601, with accession number CCTCC NO: V202604. The virus titer reaches 10. 7.5 TCID 50 / mL. This virus can be used to construct an animal model of canine adenovirus type I infection, which exhibits typical clinical symptoms, such as hepatic hemorrhage, hepatocellular necrosis, and venous and sinusoidal congestion. The constructed animal model can be used for future canine adenovirus vaccine development, immune protection assessment, and efficacy evaluation of preventive and therapeutic drugs, providing excellent biological materials and theoretical basis for further control of canine adenovirus type I.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The invention discloses a multi-mode hepatocellular carcinoma prognosis prediction method based on femtosecond laser pathological images. The method comprises the following steps: a) data acquisition and preprocessing; b) FLI feature extraction; according to the method, space and channel feature decoupling and denoising are achieved through multi-scale channel selection, channel self-attention and spatial filtering, FLI features, pathological report features and clinical data features are deeply fused through multi-modal residual feature fusion, and the accuracy and robustness of prognosis prediction are effectively improved.

Provided herein are completely defined two-dimensional culture conditions, including culture supplements and requirements for an extracellular matrix, facilitating the expansion of and long-term maintenance of primary human hepatocytes, as well as culture conditions and media for maturation of hepatocytes.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The antioxidant activity of alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and of alpha-tocopherol succinate (TS) has been examined in isolated hepatocytes and microsomal fractions from rat liver. Both TPGS and TS require esterase activity to yield free alpha-tocopherol and, hence, antioxidant activity. TPGS and TS consistently exerted a more effective antioxidant protection than an equivalent amount of directly-added free alpha-tocopherol. The low antioxidant efficiency of directly added free alpha-tocopherol in such water-based experimental systems as used here seems to be due to its extreme hydrophobicity. TPGS, on the other hand, is an extremely hydrophilic compound which is being examined as a useful source of alpha-tocopherol in certain clinical situations and is here shown to be a convenient and effective source for experimental studies into lipid peroxidation and antioxidant mechanisms.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The present invention relates to surface-functionalized extracellular vehicles. Specifically, the present invention relates to exosomes surface-functionalized with lactosylated polyetheneimine (PEI-LA), such surface-functionalized exosomes as drug delivery vehicles, 5 compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to liver.

The present invention relates to an in vitro method for predicting the response to immunotherapy treatment of hepatocellular carcinoma in a subject, comprising the following steps: 1) A step of determining the energy metabolic state of a liver tissue sample from a subject, wherein the sample comprises pathological tissue and optionally non-pathological tissue, 2) A step of detecting the presence or absence of energy conversion resulting from a reduction in mitochondrial respiration in the pathological tissue by comparing it with a liver tissue sample of the subject or a non-pathological tissue from a standard non-pathological liver sample, Here: - If mitochondrial respiration is reduced in pathological tissue, the subject is less likely to respond to immunotherapy treatment, and - If mitochondrial respiration is not reduced in the pathological tissue, the subject is highly likely to respond to immunotherapy treatment.

The invention provides a pharmaceutical composition for treating liver injury and hepatic fibrosis, and relates to the technical field of biological medicines. The pharmaceutical composition is prepared from a peucedanum decursum extract, a penthorum chinense pursh extract, a spanishneedles herb extract and a nux prinsepiae extract. The pharmaceutical composition shows an excellent protective effect on a carbon tetrachloride induced hepatocyte injury model. The pharmaceutical composition disclosed by the invention has obvious treatment and protection effects on carbon tetrachloride induced rat hepatic fibrosis, and the anti-hepatic fibrosis effect is realized by improving four indexes of liver function and hepatic fibrosis, reducing the level of inflammatory factors in the liver and relieving inflammatory reaction in the hepatic fibrosis process. The pharmaceutical composition disclosed by the invention is expected to be further developed and popularized as a medicine for treating liver injury and hepatic fibrosis.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.